Advanced Cell Technologies (ACT) provide first report on transplanting human embryonic stem cells into human patients

A first report on the 4-month follow up of two patients that received sub-retinal injections of human embryonic stem cell (hESC)-derived RPE has been published in The Lancet (Jan 23, 2012). The study, led by Prof. Steven Schwartz at the Jules Stein Eye Institute, UCLA, was sponsored by the Santa Monica-based biotech company, Advanced Cell Technology, Inc (OTCBB: ACTC). Preliminary data from the treatments provided to a patient with dry age-related macular degeneration and a patient with Stargardt’s macular dystrophy appeared to be well tolerated and had no serious adverse events.